Cybrexa.png
Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity
02 avr. 2019 08h00 HE | Cybrexa Therapeutics
Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors   Poster presentation today during AACR Annual Meeting 2019 ...
Biodesix_lockup_r_rgb (2).jpg
Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR
26 mars 2019 09h00 HE | Biodesix, Inc.
BOULDER, Colo., March 26, 2019 (GLOBE NEWSWIRE) -- Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib,...
Cybrexa.png
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
18 mars 2019 08h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., March 18, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...